Advertisement
U.S. markets closed

CSPC Pharmaceutical Group Limited (1093.HK)

HKSE - HKSE Delayed Price. Currency in HKD
6.100-0.020 (-0.33%)
At close: 04:08PM HKT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.120
Open6.140
Bid6.100 x 0
Ask6.110 x 0
Day's Range5.940 - 6.140
52 Week Range5.200 - 8.890
Volume37,942,675
Avg. Volume38,886,603
Market Cap72.61B
Beta (5Y Monthly)0.71
PE Ratio (TTM)10.89
EPS (TTM)0.560
Earnings DateMar 20, 2024 - Mar 25, 2024
Forward Dividend & Yield0.28 (4.59%)
Ex-Dividend DateSep 07, 2023
1y Target Est9.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 1093.HK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      UPDATE 1-China's CSPC Pharma partners with Pfizer for oral COVID treatment

      Chinese drug maker CSPC Pharmaceutical Group said on Thursday it signed a strategic partnership with Pfizer to launch a local brand of an oral COVID-19 treatment, in an attempt to improve the access for treatment in China. The combination of Nirmatrelvir and Ritonavir sold under the brand name Paxlovid, an oral small molecule developed by pharmaceutical company Pfizer, is used to treat patients suffering from mild to moderate COVID-19 symptoms and who are at the risk of disease progression. China, whose home-grown vaccines are seen as less effective than the Moderna and Pfizer-BioNTech mRNA shots, has been racing to develop vaccines using messenger RNA (mRNA) technology since early 2020.

    • PR Newswire

      Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

      Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, together with CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093), today announced promising initial clinical data for SYSA1801 (EO-3021) from the ongoing Phase 1 dose escalation and expansion study in China. These data will be presented at the American Society of Cli

    • PR Newswire

      Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

      Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that an abstract featuring SYSA1801 (EO-3021) Phase 1 clinical data has been selected for a poster presentation and poster discussion at the upcoming American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023 in Chicago,